The Use of "Acellbia"-A Biosimilar of Rituximab in Systemic Sclerosis.

Autor: Ananyeva LP; Nasonova Research Institute of Rheumatology, Moscow, Russia. lpana@yandex.ru., Garzanova LA; Nasonova Research Institute of Rheumatology, Moscow, Russia., Desinova OV; Nasonova Research Institute of Rheumatology, Moscow, Russia. lyuda-garzanova@yandex.ru., Shayakhmetova RU; Nasonova Research Institute of Rheumatology, Moscow, Russia., Starovoitova MN; Nasonova Research Institute of Rheumatology, Moscow, Russia., Koneva OA; Nasonova Research Institute of Rheumatology, Moscow, Russia., Ovsyannikova OB; Nasonova Research Institute of Rheumatology, Moscow, Russia., Glukhova SI; Nasonova Research Institute of Rheumatology, Moscow, Russia., Nasonov EL; Nasonova Research Institute of Rheumatology, Moscow, Russia.; Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University), Moscow, Russia.
Jazyk: angličtina
Zdroj: Doklady. Biochemistry and biophysics [Dokl Biochem Biophys] 2024 Aug; Vol. 517 (1), pp. 140-147. Date of Electronic Publication: 2024 Jun 10.
DOI: 10.1134/S1607672924700844
Abstrakt: The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a disease-modifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One example is anti-B-cell therapy, in particular rituximab (RTX). Until now RTX does not have a registration for the treatment of SSc, but there is a large positive experience of its use, which is reflected in recent meta-analyses and clinical recommendations. Complicated and expensive methods for obtaining genetically engineered biological drugs (biologics) have contributed to the emergence of more accessible biosimilars, one of which is the RTX biosimilar, Acellbia (Biocad, Russian Federation). The ''biosimilar'' versions of RTX might reduce the cost of therapy and increase patients accessibility to this treatment option. The RTX biosimilar Acellbia (ACB) has received approval in Russian Federation in 2014 for all indications held by reference RTX (including rheumatoid arthritis and ANCA-associated vasculitis).
(© 2024. Pleiades Publishing, Ltd.)
Databáze: MEDLINE
Externí odkaz: